Full-Time
Thought Leader Liaison
West Coast
Invivyd
51-200 employees
Develops monoclonal antibodies for viral protection
Compensation Overview
$184k - $245k/yr
Los Angeles, CA, USA
Hybrid
 Growth & Marketing (1) |
|---|
- 7+ years of experience in pharmaceutical or biotechnology sales, or, with a focus on institutional customers
- Field marketing or HCP marketing experience
- In-depth knowledge of the healthcare industry, specifically institutional accounts
- Experience in Hematology, Transplant, Rheumatology, and Infectious Disease preferred
- KOL (Key Opinion Leader) Healthcare Provider Identification and Engagement
- Market Insight Gathering on current disease management landscape
- Speaker Bureau Management, including HCP Speaker Identification, Engagement and Training and HCP Speaker Bureau Content Creation
- HCP and Patient Congress Engagements, including KOL interactions with Invivyd leadership
- Support and Execution of Strategic Marketing Initiatives
- Proactive interactions with KOLs to validate and optimize brand strategies
- Collaboration on the development of HCP and Patient marketing materials to support effective HCP and Patient Engagement
- Collaboration with local/ regional advocacy groups to develop and coordinate community engagement webinars aimed at improving patient awareness and understanding of the disease and management options
Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.
Company Size
51-200
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2020
Simplify's Take
What believers are saying
- PEMGARDA Q4 2025 revenue hit $17.2M, up 31% sequentially.
- VYD2311 Phase 3 trial fully enrolled, data due mid-2026 with FDA Fast Track.
- Appointed Harvard epidemiologist Michael Mina as Chief Medical Officer.
What critics are saying
- Kahn Swick & Foti investigates officers over Adagio's 2021 IPO.
- Low COVID-19 attack rates fail VYD2311 trial by mid-2026.
- FDA revokes PEMGARDA EUA due to NB.1.8.1 variant escape in 2026.
What makes Invivyd unique
- Proprietary platform combines viral surveillance, predictive modeling, and antibody engineering.
- Develops vaccine-alternative monoclonal antibodies for immunocompromised patients.
- Targets COVID-19, RSV, measles with pediatric-first approach via REVOLUTION program.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Invivyd who can refer or advise you
Benefits
Remote Work Options
Professional Development Budget
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -5%2 year growth
↓ -1%Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.
Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.
Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.
Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.
Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.